NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.3 Sex hormones and hormone antagonists in malignant disease > 8.3.4 Hormone antagonists > 8.3.4.1 Breast Cancer > Breast cancer (metastatic) - fulvestrant - NICE TAG TA239

Breast cancer (metastatic) - fulvestrant - NICE TAG TA239

1.1 Fulvestrant is not recommended, within its licensed indication, as an alternative to aromatase inhibitors for the treatment of oestrogen-receptor-positive, locally advanced or metastatic breast cancer in postmenopausal women whose cancer has relapsed on or after adjuvant anti-oestrogen therapy, or who have disease progression on anti-oestrogen therapy.

1.2 Post-menopausal women currently receiving fulvestrant within its licensed indication as an alternative to aromatase inhibitors for the treatment of oestrogen-receptor-positive, locally advanced or metastatic breast cancer whose cancer has relapsed on or after adjuvant anti-oestrogen therapy, or who have disease progression on anti-oestrogen therapy, should have the option to continue treatment until they and their clinicians consider it appropriate to stop.

http://www.nice.org.uk/guidance/TA239

Site by Devopa
© Copyright 2019 NHS. All rights reserved.